Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Risk of Autoimmune Disorders Associated with GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT2 Inhibitors in Diabetic Patients

  • By

  • Arjun Mahajan

  • David W. Bates

  • Alessandro Doria

  • Dinah Foer

  • Avery H. LaChance

  • Jeffrey A. Sparks

  • July 1, 2026

Share

Original Source(s)

Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes

  • by Arjun Mahajan, David W. Bates, Alessandro Doria, Dinah Foer, Avery H. LaChance, Jeffrey A. Sparks

  • July 1, 2026

Related Content

Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation

Sexual dysfunction associated with antidepressants and antipsychotics: a structured narrative review of mechanisms, assessment, and personalized management

Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis